Drug intelligence / Profile preview

pGDNF_1b

Development stage
Preclinical
Modality
Gene Silencing → Gene Therapies, Gene Editing → Gene Therapies, Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Gene Addition/Replacement → Gene Therapies
Administration
Intracerebral, Intrastriatal
01

Overview

pGDNF_1b is a DNA plasmid encoding the human glial cell line–derived neurotrophic factor (GDNF) splice variant 1, delivered as a compacted DNA nanoparticle for gene therapy. It uses the polyubiquitin C (UbC) promoter active primarily in glia, and its cassette design includes flanking scaffold/matrix attachment elements and a CpG-depleted prokaryotic domain to enhance expression. Intracerebral administration of pGDNF_1b nanoparticles results in sustained, long-term GDNF expression at biologically active levels, aiming for neuroprotection in models of Parkinson’s disease. Its mechanism is gene-mediated overexpression of GDNF to support neuron survival and function, particularly in the striatum.

Other names
pGDNF nanoparticlesGDNF plasmid nanoparticlesnano-GDNFGDNF-pDNA nanoparticles
02

Targets

GDNF (Glial cell line-derived neurotrophic factor)

Beyond the preview

Go deeper on pGDNF_1b.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on pGDNF_1b.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call